UK Markets closed
  • NIKKEI 225

    27,433.40
    +50.84 (+0.19%)
     
  • HANG SENG

    22,069.73
    -619.17 (-2.73%)
     
  • CRUDE OIL

    77.81
    -1.87 (-2.35%)
     
  • GOLD FUTURES

    1,939.00
    -6.60 (-0.34%)
     
  • DOW

    33,717.09
    -260.99 (-0.77%)
     
  • BTC-GBP

    18,388.72
    -953.72 (-4.93%)
     
  • CMC Crypto 200

    514.97
    -22.91 (-4.26%)
     
  • Nasdaq

    11,393.81
    -227.90 (-1.96%)
     
  • ^FTAS

    4,265.16
    +6.19 (+0.15%)
     

Insights on the Canine Atopic Dermatitis Global Market to 2027 - Increasing Occurrence of CAD in Domesticated Dogs Drives Growth

Company Logo
Company Logo

Global Canine Atopic Dermatitis Market

Global Canine Atopic Dermatitis Market
Global Canine Atopic Dermatitis Market

Dublin, Jan. 06, 2023 (GLOBE NEWSWIRE) -- The "Canine Atopic Dermatitis Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.

The global canine atopic dermatitis market size reached US$ 1.56 Billion in 2021. Looking forward, the publisher expects the market to reach US$ 3.89 Billion by 2027, exhibiting a CAGR of 16.45% during 2021-2027.

Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.

Canine atopic dermatitis (CAD) is an allergic skin disease in dogs caused by allergens, such as pollens, house dust, insect bites, grass and food ingredients.

It is an inherited predisposition that generally affects dogs aged between six months to three years. It commonly affects the ventral abdomen, mouth, eyes, interdigital skin, ear pinnae, carpal, elbow and perineal area of the animals. CAD is characterized by various symptoms, such as excessive scratching, inflammation and itching around paws, underarms and face.

It can be treated by immuno-suppressants, monoclonal anatomy and glucocorticoids. They can be administered through oral, injectables and topical medications. It is known to be highly prevalent in German shepherds, Labradors, golden retrievers and pugs.

Canine Atopic Dermatitis Market Trends:

The increasing occurrence of CAD in domesticated dogs across the globe is one of the key factors creating a positive outlook for the market. This can be attributed to the changing environmental conditions, rising air pollution levels and prolonged exposure to allergens.

Moreover, the increasing concerns and rising awareness among pet owners regarding early symptoms and signs of CAD, such as redness, greasy skin and yeasty smell, are providing a thrust to the market growth.

Additionally, the widespread adoption of monoclonal antibodies for the treatment of the disease is favoring the market growth. These antibodies aid in directing the required immune response and calming the spread of the disease. In line with this, the increasing number of veterinary practitioners, hospitals and clinics dedicated to providing improved care for animals is positively impacting the market growth.

Other factors, including the implementation of various government initiatives to restrict the usage of off-label human drugs on animals, along with extensive research and development (R&D) in the field of veterinary sciences, are anticipated to drive the market toward growth.

Key Market Segmentation:

The publisher provides an analysis of the key trends in each sub-segment of the global canine atopic dermatitis market report, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on drug class type, route of administration and distribution channel.

Breakup by Drug Class Type:

  • Glucocorticoids

  • Immunosuppressants

  • Monoclonal Antibody

  • Others

Breakup by Route of Administration:

  • Topical

  • Oral

  • Injectable

Breakup by Distribution Channel:

  • Veterinary Hospitals

  • Pet Clinics

  • Pharmacies and Drugstores

  • Others

Breakup by Region:

  • North America

  • United States

  • Canada

  • Asia-Pacific

  • China

  • Japan

  • India

  • South Korea

  • Australia

  • Indonesia

  • Others

  • Europe

  • Germany

  • France

  • United Kingdom

  • Italy

  • Spain

  • Russia

  • Others

  • Latin America

  • Brazil

  • Mexico

  • Others

  • Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being AB Science, Bimeda Inc., Bioceltix SA, Boehringer Ingelheim International GmbH, Ceva Sante Animale, Dechra Pharmaceuticals PLC, Elanco Animal Health Incorporated, Phibro Animal Health Corporation, Toray Industries Inc., Vetoquinol S.A., Virbac and Zoetis Inc.

Key Questions Answered in This Report:

  • How has the global canine atopic dermatitis market performed so far and how will it perform in the coming years?

  • What has been the impact of COVID-19 on the global canine atopic dermatitis market?

  • What are the key regional markets?

  • What is the breakup of the market based on the drug class type?

  • What is the breakup of the market based on the route of administration?

  • What is the breakup of the market based on the distribution channel?

  • What are the various stages in the value chain of the industry?

  • What are the key driving factors and challenges in the industry?

  • What is the structure of the global canine atopic dermatitis market and who are the key players?

  • What is the degree of competition in the industry?

Report Attribute

Details

No. of Pages

143

Forecast Period

2021 - 2027

Estimated Market Value (USD) in 2021

$1.56 Billion

Forecasted Market Value (USD) by 2027

$3.89 Billion

Compound Annual Growth Rate

16.4%

Regions Covered

Global

Key Topics Covered:

1 Preface

2 Scope and Methodology

3 Executive Summary

4 Introduction
4.1 Overview
4.2 Key Industry Trends

5 Global Canine Atopic Dermatitis Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast

6 Market Breakup by Drug Class Type
6.1 Glucocorticoids
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Immunosuppressants
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Monoclonal Antibody
6.3.1 Market Trends
6.3.2 Market Forecast
6.4 Others
6.4.1 Market Trends
6.4.2 Market Forecast

7 Market Breakup by Route of Administration
7.1 Topical
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Oral
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Injectable
7.3.1 Market Trends
7.3.2 Market Forecast

8 Market Breakup by Distribution Channel
8.1 Veterinary Hospitals
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Pet Clinics
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Pharmacies and Drugstores
8.3.1 Market Trends
8.3.2 Market Forecast
8.4 Others
8.4.1 Market Trends
8.4.2 Market Forecast

9 Market Breakup by Region

10 SWOT Analysis

11 Value Chain Analysis

12 Porters Five Forces Analysis

13 Price Analysis

14 Competitive Landscape
14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
14.3.1 AB Science
14.3.1.1 Company Overview
14.3.1.2 Product Portfolio
14.3.1.3 Financials
14.3.2 Bimeda Inc.
14.3.2.1 Company Overview
14.3.2.2 Product Portfolio
14.3.3 Bioceltix SA
14.3.3.1 Company Overview
14.3.3.2 Product Portfolio
14.3.4 Boehringer Ingelheim International GmbH
14.3.4.1 Company Overview
14.3.4.2 Product Portfolio
14.3.5 Ceva Sante Animale
14.3.5.1 Company Overview
14.3.5.2 Product Portfolio
14.3.6 Dechra Pharmaceuticals PLC
14.3.6.1 Company Overview
14.3.6.2 Product Portfolio
14.3.6.3 Financials
14.3.7 Elanco Animal Health Incorporated
14.3.7.1 Company Overview
14.3.7.2 Product Portfolio
14.3.7.3 Financials
14.3.8 Phibro Animal Health Corporation
14.3.8.1 Company Overview
14.3.8.2 Product Portfolio
14.3.8.3 Financials
14.3.8.4 SWOT Analysis
14.3.9 Toray Industries Inc.
14.3.9.1 Company Overview
14.3.9.2 Product Portfolio
14.3.9.3 Financials
14.3.9.4 SWOT Analysis
14.3.10 Vetoquinol S.A.
14.3.10.1 Company Overview
14.3.10.2 Product Portfolio
14.3.10.3 Financials
14.3.11 Virbac
14.3.11.1 Company Overview
14.3.11.2 Product Portfolio
14.3.11.3 Financials
14.3.11.4 SWOT Analysis
14.3.12 Zoetis Inc.
14.3.12.1 Company Overview
14.3.12.2 Product Portfolio
14.3.12.3 Financials
14.3.12.4 SWOT Analysis

For more information about this report visit https://www.researchandmarkets.com/r/ofszo7

Attachment

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900